Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 NET 1 Gastrointestinal 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Specimen Handling 9 Magnetic Resonance Spectroscopy 9 lutetium Lu 177 dotatate 6 cabozantinib 6 Nivolumab 5 Ipilimumab 4 fludarabine 3 X-Rays 3 Phantoms, Imaging 3 Etoposide 3 Cyclophosphamide 3 CTLA-4 Antigen 3 pembrolizumab 2 olaparib 2 aldesleukin 2 Lutetium-177 2 Lutetium 2 Irinotecan 2 Cisplatin 2 Carboplatin 2 trametinib 1 tivozanib 1 tipifarnib 1 selpercatinib 1 repotrectinib 1 pazopanib 1 gallium Ga 68 dotatate 1 gallium 68 PSMA-11 1 fluorodopa F 18 1 fluorocholine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Yttrium-90 × Endocrine × 30 days × Clear all

NCT04339036 2026-06-04

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡